All 6 resolutions passed at Norris Medicines 35th AGM
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts less than Nifty Microcap 250 and 5.0 pts less than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Norris Medicines held its 35th AGM on Sep 29, 2026 via video conferencing. All 6 resolutions passed. About 67% of shares were voted. With over 99% support, shareholders approved: FY26 audited financials, re-appointment of Praveen J. Bafna as director, appointment of Vimal D. Shah as Managing Director (promoter interested), increase in borrowing limits, authorization to sell or lease the companys undertaking, and enhancement of Section 186 investment limits.
Routine approvals with strong shareholder backing. New borrowing and disposal authorizations give the board more financial flexibility.